A histone deacetylase inhibitor, largazole, decreases liver fibrosis and angiogenesis by inhibiting transforming growth factor-β and vascular endothelial growth factor signalling

Total synthesis of largazole and analogues: HDAC inhibition, antiproliferative activity and metabolic stability

(2011) Hanae Benelkebir et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Inhibition of PDGF, TGF-β, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib

(2011) Yuqing Liu et al.   JOURNAL OF HEPATOLOGY

Synthesis and Biological Characterization of the Histone Deacetylase Inhibitor Largazole and C7- Modified Analogues

(2010) José A. Souto et al.   JOURNAL OF MEDICINAL CHEMISTRY

Total Synthesis and Biological Evaluation of Largazole and Derivatives with Promising Selectivity for Cancers Cells

(2010) Xin Zeng et al.   ORGANIC LETTERS

Changes in microRNAs associated with hepatic stellate cell activation status identify signaling pathways

(2009) Can-Jie Guo et al.   FEBS Journal

Chronic administration of valproic acid inhibits activation of mouse hepatic stellate cellsin vitroandin vivo

(2009) Inge Mannaerts et al.   HEPATOLOGY

Hepatic Stellate Cells Secrete Angiopoietin 1 That Induces Angiogenesis in Liver Fibrosis

(2008) Kojiro Taura et al.   GASTROENTEROLOGY

Mechanisms of Hepatic Fibrogenesis

(2008) Scott L. Friedman   GASTROENTEROLOGY

Total Synthesis and Biological Mode of Action of Largazole: A Potent Class I Histone Deacetylase Inhibitor

(2008) Albert Bowers et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Structure and Activity of Largazole, a Potent Antiproliferative Agent from the Floridian Marine CyanobacteriumSymplocasp.

(2008) Kanchan Taori et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY